Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0QETUG
ADC Name
N297Q ADC
Synonyms
tubulysin-aMeso PEG ADC (N297Q ADC)
   Click to Show/Hide
Organization
Bristol Myers Squibb.
Drug Status
Investigative
Drug-to-Antibody Ratio
3.3
Structure
Antibody Name
undisclosed
Antigen Name
Mesothelin (MSLN)
  Antigen Info 
Payload Name
Undisclosed
Therapeutic Target
Stimulator of interferon genes protein (STING1)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Site-specific conjugation at N297Q.
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
Click To Hide/Show 2 Absorption Data Related to This Level
Standard Type Value Units Description Reference
Maximum Observed Concentration (Cmax) 7229 ng/mL
PK parameters of three ADCs dosed at 0.5 mg/kg in vivo.
 [1]
Area Under the Concentration-Time Curve (AUC) 1172 h&#42ug/mL
PK parameters of three ADCs dosed at 0.5 mg/kg in vivo, AUC0-336h.
 [1]
Distribution
Click To Hide/Show 1 Distribution Data Related to This Level
Standard Type Value Units Description Reference
Area Under the Concentration-Time Curve (AUC) 1172 h&#42ug/mL
PK parameters of three ADCs dosed at 0.5 mg/kg in vivo, AUC0-336h.
 [1]
Metabolism
Click To Hide/Show 1 Metabolism Data Related to This Level
Standard Type Value Units Description Reference
Area Under the Concentration-Time Curve (AUC) 1172 h&#42ug/mL
PK parameters of three ADCs dosed at 0.5 mg/kg in vivo, AUC0-336h.
 [1]
Excretion
Click To Hide/Show 2 Excretion Data Related to This Level
Standard Type Value Units Description Reference
Area Under the Concentration-Time Curve (AUC) 1172 h&#42ug/mL
PK parameters of three ADCs dosed at 0.5 mg/kg in vivo, AUC0-336h.
 [1]
Elimination Half-Life (t1/2) 334 h
PK parameters of three ADCs dosed at 0.5 mg/kg in vivo.
 [1]
References
Ref 1 The Impact of Conjugation Mode and Site on Tubulysin Antibody-Drug-Conjugate Efficacy and Stability